HOME >> BIOLOGY >> NEWS
Highlights from October ESA journals

From Frontiers in Ecology and the Environment

How many endangered species are there in the United States?

With only 15 percent of known species in the United States studied well enough to determine if they are imperiled or not, David Wilcove (Princeton University, US) and Lawrence Master (NatureServe, US) review and extrapolate the actual number of species in danger, based on the numbers we do have.

Reviews in Frontiers

Reviews in the October issue of Frontiers include merging land and sea conservation by considering the ecological interactions between the two in "Integrated coastal reserve planning: making the land-sea connection," and the conservation of cultural resources in "Microbial deterioration of historic stone."

From Ecology

Wandering albatrosses

Wandering albatrosses (Diomedea exulans) soar across the Indian Ocean for thousands of kilometers in a single trip, scouring the ocean for food. Henri Weimerskirch and colleagues from the National Scientific Research Center and the Natural History Museum of France, tracked the foraging behavior of the birds in "Prey Distribution and Patchiness: Factors in Foraging Success and Efficiency of Wandering Albatrosses," which appears in the October issue of Ecology. The study indicates this species has a unique foraging strategy. Unlike most seabirds, which concentrate on more predictable foraging areas, the researchers report that wandering albatrosses rely on prey that are highly dispersed, catch few prey in the same areas, and do not adjust their foraging to maximize their energy requirements.

Coral reef fish impacted by nuclear tests

France conducted a series of underground nuclear tests between 1976 and 1995 near the Mururoa Atoll in the South Pacific Ocean. Controlled underground explosions kept radiation from reaching fish; pressure waves from the testing killed them. Using nearby study sites, Fre
'"/>

Contact: Annie Drinkard
annie@esa.org
Ecological Society of America
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Highlights from the July 2007 Journal of the American Dietetic Association
2. AGU Journal Highlights -- April 16, 2007
3. Highlights from the April 2007 Journal of the American Dietetic Association
4. Highlights from the January 2007 Journal of the American Dietetic Association
5. Highlights from the December 2006 Journal of the American Dietetic Association
6. Highlights from the November 2006 Journal of the American Dietetic Association
7. Highlights from the October 2006 Journal of the American Dietetic Association
8. Highlights from the September 2006 Journal of the American Dietetic Association
9. Highlights from the August 2006 Journal of the American Dietetic Association
10. Highlights from the June 2006 Journal of the American Dietetic Association
11. Highlights from the May 2006 Journal of the American Dietetic Association

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Highlights from October ESA journals

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: